PS
ANIP icon

Principal Securities’s ANI Pharmaceuticals ANIP Stock Holding History

Principal Securities’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$1.47K – 1444
2025
Q3 		$1.47K Hold
16
– – ﹤0.01% 3306
2025
Q2 		$1.04K Buy
16
+10
+167% +$651 ﹤0.01% 3323
2025
Q1 		$332 Hold
6
– – ﹤0.01% 3410
2024
Q4 		$332 Buy
+6
New +$344 ﹤0.01% 3405

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's ANIP Position: Q4 2025 in Review

Principal Securities sold out of ANI Pharmaceuticals (ANIP) in Q4 2025, closing a stake of 16 shares — an estimated $1.47K sold.

Principal Securities first reported a position in ANIP in Q4 2024 and held it in 4 quarters. The position peaked at $1.47K in Q3 2025. 284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • Principal Securities reported no remaining ANI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 16 ANI Pharmaceuticals shares in Q4 2025, an estimated $1.47K.
  • Principal Securities first reported a position in ANI Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Principal Securities's ANI Pharmaceuticals position peaked at $1.47K in Q3 2025.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.